文献速递胃肠外科围术期管理与 ERAS

Pudexacianinium (ASP5354) 氯化物用于腹腔镜结直肠手术中输尿管显影:2期研究

Pudexacianinium (ASP5354) chloride for ureter visualization in participants undergoing laparoscopic, minimally invasive colorectal surgery.
PubMed 文献 · Surg Endosc · 2023-07-20

这项2期研究将接受腹腔镜结直肠手术的成人随机分配至单次静脉注射pudexacianinium 0.3 mg、1.0 mg或3.0 mg,主要终点为术中输尿管显影成功。结果显示1.0 mg和3.0 mg剂量在手术全程提供输尿管显影,安全且耐受性良好。

要点

  • 1.0 mg和3.0 mg pudexacianinium可在腹腔镜结直肠手术全程实现输尿管显影。
  • 荧光强度随剂量增加:0.3 mg为轻度、1.0 mg为中度、3.0 mg为强。
  • 安全性和耐受性良好,仅1例1级蛋白尿与药物相关。

核心结论

  • 1.0 mg和3.0 mg pudexacianinium在微创腹腔镜结直肠手术期间提供输尿管显影,且安全、耐受性良好。

研究设计与样本

  • 2期研究(NCT04238481),接受腹腔镜结直肠手术的成人随机接受单次静脉注射pudexacianinium 0.3 mg(n=3)、1.0 mg(n=6)或3.0 mg(n=3)。

主要发现

  • 术中输尿管显影成功例数分别为0.3 mg组2/3、1.0 mg组5/6、3.0 mg组3/3。
  • 外科医生评估的中位荧光强度:0.3 mg为1(轻度),1.0 mg为2(中度),3.0 mg为3(强)。
  • 定性(术中外科医生识别)与定量(术后视频录像)荧光强度评估之间观察到相关性。
  • 2例参与者发生严重不良事件,均非药物相关毒性;1例1级蛋白尿与pudexacianinium相关。
  • 血浆浓度呈剂量依赖性,术中尿排泄平均百分比:0.3 mg组22.3%±8.0%,1.0 mg组15.6%±10.0%,3.0 mg组39.5%±12.4%。

关键数值与推荐

  • 主要终点为术中输尿管显影成功,定义为给药后30分钟及手术结束时观察到输尿管荧光。

临床怎么用

  • 在腹腔镜结直肠手术中,可考虑使用pudexacianinium 1.0 mg或3.0 mg进行术中输尿管显影,以辅助识别输尿管、降低损伤风险。

局限性

  • 每组样本量小(0.3 mg组3例、1.0 mg组6例、3.0 mg组3例)。
  • 多数参与者为女性(10/12,83.3%),中位年龄54岁(范围24-69),中位BMI 29.3 kg/m2(范围18.7-38.1),结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraoperative ureteral injury, a serious complication of abdominopelvic surgeries, can be avoided through ureter visualization. Near-infrared fluorescence imaging offers real-time anatomical visualization of ureters during surgery. Pudexacianinium (ASP5354) chloride is an indocyanine green derivative under investigation for intraoperative ureter visualization during colorectal or gynecologic surgery in adult and pediatric patients. METHODS: In this phase 2 study (NCT04238481), adults undergoing laparoscopic colorectal surgery were randomized to receive one intravenous dose of pudexacianinium 0.3 mg, 1.0 mg, or 3.0 mg. The primary endpoint was successful intraoperative ureter visualization, defined as observation of ureter fluorescence 30 min after pudexacianinium administration and at end of surgery. Safety and pharmacokinetics were also assessed. RESULTS: Participants received pudexacianinium 0.3 mg (n = 3), 1.0 mg (n = 6), or 3.0 mg (n = 3). Most participants were female (n = 10; 83.3%); median age was 54 years (range 24-69) and median BMI was 29.3 kg/m2 (range 18.7-38.1). Successful intraoperative ureter visualization occurred in 2/3, 5/6, and 3/3 participants who received pudexacianinium 0.3 mg, 1.0 mg, or 3.0 mg, respectively. Median intensity values per surgeon assessment were 1 (mild) with the 0.3-mg dose, 2 (moderate) with the 1.0-mg dose, and 3 (strong) with the 3.0-mg dose. A correlation was observed between qualitative (surgeon's recognition/identification of the ureter during surgery) and quantitative (video recordings of the surgeries after study completion) assessment of fluorescence intensity. Two participants experienced serious adverse events, none of which were drug-related toxicities. One adverse event (grade 1 proteinuria) was related to pudexacianinium. Plasma pudexacianinium concentrations were dose-dependent and the mean (± SD) percent excreted into urine during surgery was 22.3% ± 8.0% (0.3-mg dose), 15.6% ± 10.0% (1.0-mg dose), and 39.5% ± 12.4% (3.0-mg dose). CONCLUSIONS: In this study, 1.0 and 3.0 mg pudexacianinium provided ureteral visualization for the duration of minimally invasive, laparoscopic colorectal procedures and was safe and well tolerated.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Albert M, Delgado-Herrera L, Paruch J, et al. Pudexacianinium (ASP5354) chloride for ureter visualization in participants undergoing laparoscopic, minimally invasive colorectal surgery. Surg Endosc. 2023. PMID: 37474823. doi:10.1007/s00464-023-10193-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。